** Shares of drug developer LAVA Therapeutics rise 10.2% to $3.34 premarket
** Company says it has received a milestone payment of $7 mln from Pfizer as its experimental cancer drug PF-08046052 entered into early-stage trials
** LVTX had given exclusive license for the drug to Seagen in 2022, which was acquired by PFE last year
** LVTX received $50 mln upfront payment and is eligible to receive up to ~$650 mln in milestone plus royalties
** Up to last close, stock up 24.2% in the last 12 months
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments